SUNPHARMA.BO Sun Pharmaceutical Industries Limited
BSEHealthcareAs of 2026-06-03 06:14
Valuation
View DetailsP/E (TTM)
37.42
PEG
—
P/B
5.14
P/S
7.34
EV/EBITDA
25.79
DCF Value
—
FCF Yield
0.6%
Div Yield
0.9%
Margins & Returns
Gross Margin
55.7%
Operating Margin
23.2%
Net Margin
19.6%
ROE
15.0%
ROA
10.6%
ROIC
11.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2026 | $146.12B | $27.14B | $11.30 |
| Q3 2026 | $155.21B | $33.69B | $14.04 |
| Q2 2026 | $144.78B | $31.18B | $13.00 |
| Q1 2026 | $138.51B | $22.79B | $9.50 |
Listing Info
Market
US
Exchange
BSE
Currency
USD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
IN
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and anti retro viral medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.